Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.
作者信息
Abdel-Magid Ahmed F
机构信息
Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States.
出版信息
ACS Med Chem Lett. 2021 Jan 22;12(2):182-184. doi: 10.1021/acsmedchemlett.1c00017. eCollection 2021 Feb 11.
Abstract
摘要
相似文献
1
Potential of Cyclin-Dependent Kinase Inhibitors as Cancer Therapy.细胞周期蛋白依赖性激酶抑制剂作为癌症治疗手段的潜力
ACS Med Chem Lett. 2021 Jan 22;12(2):182-184. doi: 10.1021/acsmedchemlett.1c00017. eCollection 2021 Feb 11.
2
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.转移性激素受体阳性乳腺癌中细胞周期蛋白依赖性激酶抑制后的治疗：耐药机制和新的治疗策略。
Cancer. 2020 Aug 1;126(15):3400-3416. doi: 10.1002/cncr.32931. Epub 2020 May 19.
3
Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.细胞周期蛋白依赖性激酶4/6抑制剂在当前及未来癌症治疗时代的作用
J Oncol Pharm Pract. 2019 Jan;25(1):110-129. doi: 10.1177/1078155218770904. Epub 2018 May 4.
4
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂相关毒性和药物相互作用的临床处理：实用注意事项和建议。
Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13.
5
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2- Breast Cancer: A Systematic Review and Meta-Analysis.CDK4/6 抑制剂联合内分泌治疗 HR+/HER2- 乳腺癌的新辅助治疗：系统评价和荟萃分析。
Oncol Res Treat. 2021;44(10):557-567. doi: 10.1159/000518573. Epub 2021 Aug 12.
6
Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.腺病毒介导的E2F-1基因转移在人胃癌细胞中诱导凋亡反应，细胞周期蛋白依赖性激酶抑制剂可增强这种反应。
Int J Mol Med. 2000 Jul;6(1):55-63. doi: 10.3892/ijmm.6.1.55.
7
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.细胞周期蛋白依赖性激酶 4/6 抑制剂治疗激素受体阳性晚期乳腺癌的研究进展。
Ann Pharmacother. 2019 Feb;53(2):195-203. doi: 10.1177/1060028018793656. Epub 2018 Aug 6.
8
Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges.用细胞周期蛋白依赖性激酶抑制剂进行抗癌治疗：影响和挑战。
Expert Rev Mol Med. 2021 Jun 9;23:e6. doi: 10.1017/erm.2021.3.
9
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG).CDK4/6 抑制剂在激素受体阳性、人表皮生长因子受体 2 阴性、转移性乳腺癌中的应用：乳腺癌治疗专家小组（BCTEG）的圆桌讨论。
Breast Cancer Res Treat. 2018 Aug;171(1):11-20. doi: 10.1007/s10549-018-4783-1. Epub 2018 May 4.
10
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.对细胞周期蛋白依赖性激酶（CDK）4/6抑制剂的耐药性赋予了乳腺癌细胞对其他CDK抑制剂的交叉耐药性，但对化疗药物没有交叉耐药性。
Breast Cancer. 2021 Jan;28(1):206-215. doi: 10.1007/s12282-020-01150-8. Epub 2020 Aug 28.
引用本文的文献
1
Targeting the cyclin D/CDK4 Axis to unlock new therapeutic approaches to enhance cancer treatment.靶向细胞周期蛋白D/细胞周期蛋白依赖性激酶4轴以开启增强癌症治疗的新治疗方法。
PLoS One. 2025 Aug 22;20(8):e0330102. doi: 10.1371/journal.pone.0330102. eCollection 2025.
2
Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy.预测并克服癌症治疗中对CDK9抑制剂的耐药性。
Acta Pharm Sin B. 2023 Sep;13(9):3694-3707. doi: 10.1016/j.apsb.2023.05.026. Epub 2023 May 26.
本文引用的文献
1
Cyclin-dependent kinases and rare developmental disorders.细胞周期蛋白依赖性激酶与罕见发育障碍性疾病
Orphanet J Rare Dis. 2020 Aug 6;15(1):203. doi: 10.1186/s13023-020-01472-y.
2
Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.用于癌症治疗管理的小分子细胞周期蛋白依赖性激酶（CDK）抑制剂
Curr Top Med Chem. 2020;20(17):1535-1563. doi: 10.2174/1568026620666200516152756.
3
Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.雌激素受体阳性乳腺癌中的细胞周期蛋白 E1 和 E2：作为生物标志物和治疗靶点的前景。
Endocr Relat Cancer. 2020 May;27(5):R93-R112. doi: 10.1530/ERC-19-0501.
4
Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019).细胞周期蛋白依赖性激酶 (CDK) 抑制剂作为抗癌药物：最新进展 (2015-2019)。
Bioorg Med Chem Lett. 2019 Oct 15;29(20):126637. doi: 10.1016/j.bmcl.2019.126637. Epub 2019 Aug 26.
5
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.细胞周期蛋白依赖性激酶 2 抑制剂在癌症治疗中的应用：最新进展。
J Med Chem. 2019 May 9;62(9):4233-4251. doi: 10.1021/acs.jmedchem.8b01469. Epub 2018 Dec 20.
6
Review of Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Hormone Receptor-Positive Advanced Breast Cancer.细胞周期蛋白依赖性激酶 4/6 抑制剂治疗激素受体阳性晚期乳腺癌的研究进展。
Ann Pharmacother. 2019 Feb;53(2):195-203. doi: 10.1177/1060028018793656. Epub 2018 Aug 6.
Zotero 插件